Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

67.04
Delayed Data
As of Apr 29
 -0.84 / -1.24%
Today’s Change
51.51
Today|||52-Week Range
140.00
-28.79%
Year-to-Date
No recent news for Alnylam Pharmaceuticals Inc.

Today’s Trading

Previous close67.88
Today’s open67.68
Day’s range66.40 - 68.23
Volume426,201
Average volume (3 months)992,539
Market cap$5.8B
Dividend yield--
Data as of 4:00pm ET, 04/29/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-22.27%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book4.57

Competitors

 Today’s
change
Today’s
% change
IONSIonis Pharmaceutical...-0.02-0.05%
CRLCharles River Labora...-0.76-0.95%
ICLRICON PLC+0.44+0.66%
PRXLPAREXEL Internationa...+0.52+0.86%
Data as of 4:01pm ET, 04/29/2016

Financials

Next reporting dateMay 3, 2016
EPS forecast (this quarter)-$1.05
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs